Abstract
Lopinavir (LPV) is currently one of the most commonly used protease inhibitors in pregnant women with HIV. The aim of the study is to evaluate the influence of diabetes mellitus (DM) on the pharmacokinetics of lopinavir in HIV-infected women during the third trimester of pregnancy, at delivery and in umbilical cord. Nondiabetic HIV-infected women during the third trimester of pregnancy (c…